<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803827</url>
  </required_header>
  <id_info>
    <org_study_id>GCC 0768-05</org_study_id>
    <nct_id>NCT02803827</nct_id>
  </id_info>
  <brief_title>Optimizing the Management of Acute Diarrhoeal Disease</brief_title>
  <official_title>Optimizing the Management of Pediatric Acute Diarrhoeal Disease in Botswana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grand Challenges Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioMÃ©rieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copan Italia S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Botswana-UPenn Partnership</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many children admitted to hospital in Botswana without bloody diarrhoea are presumed to have
      viral gastroenteritis and so not treated with antibiotics - but they may indeed have a
      treatable cause for their illness. The investigators will conduct a randomized trial to see
      if rapid testing using novel methods to identify potentially treatable causes of diarrhoea
      leads to improved outcomes. The investigators will also be randomizing children to
      Lactobacillus reuteri DSM (daughter strain) 17938 therapy versus placebo (the standard of
      care) to see if this treatment decreases the duration of diarrhoea. The proposed study is a
      large multi-centre trial following the previous pilot trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Height z-score (HAZ) adjusted for baseline HAZ</measure>
    <time_frame>60 days post-enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>60 days post-enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight z-score (WAZ) adjusted for baseline WAZ</measure>
    <time_frame>60 days post-enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Environmental enteropathy score (EES)</measure>
    <time_frame>60 days</time_frame>
    <description>composite of stool neopterin, myeloperoxidase, and alpha-1-antitrypsin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhoea recurrence</measure>
    <time_frame>60 days after enrolment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Rapid diagnostics and probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid diagnostics and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given placebo x 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No rapid diagnostics and probiotic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No rapid diagnostics and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given placebo x 60 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rapid diagnostics</intervention_name>
    <description>Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.</description>
    <arm_group_label>Rapid diagnostics and probiotic</arm_group_label>
    <arm_group_label>Rapid diagnostics and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.</description>
    <arm_group_label>Rapid diagnostics and probiotic</arm_group_label>
    <arm_group_label>No rapid diagnostics and probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo will be the vegetable oil vehicle and look identical to the probiotic.</description>
    <arm_group_label>Rapid diagnostics and placebo</arm_group_label>
    <arm_group_label>No rapid diagnostics and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute diarrhoeal illness (&gt;= 3 stools in 24 hour period)

        Exclusion Criteria:

          -  diarrhoeal illness &gt;=14 days

          -  bloody stool

          -  known inflammatory bowel disease, cystic fibrosis, or malignancy

          -  live in a household with someone else documented to have a bacterial or parasitic
             enteric infection of defined aetiology

          -  live outside catchment areas

          -  no permanent address

          -  no access to mobile phone

          -  previous participation in this study

          -  nosocomial diarrhoea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Pernica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Pernica, MD</last_name>
    <phone>905 521 2100</phone>
    <phone_ext>77577</phone_ext>
    <email>pernica@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tonya Arscott-Mills, MD</last_name>
    <phone>+267 3170933</phone>
    <email>tonyaarscottmillsbup@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Princess Marina Hospital</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonya Arscott-Mills</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deborah Retief Hospital</name>
      <address>
        <city>Mochudi</city>
        <country>Botswana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Banno Moorad</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scottish Livingstone Hospital</name>
      <address>
        <city>Molepolole</city>
        <country>Botswana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boswa Ndulamo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bamalete Lutheran Hospital</name>
      <address>
        <city>Ramotswa</city>
        <country>Botswana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Banno Moorad</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Botswana</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Jeffrey Pernica</investigator_full_name>
    <investigator_title>Head, Division of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>diarrhoea</keyword>
  <keyword>gastroenteritis</keyword>
  <keyword>rapid diagnostics</keyword>
  <keyword>probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

